Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation.
about
ErbB receptors: from oncogenes to targeted cancer therapiesA functional role of the membrane-proximal extracellular domains of the signal transducer gp130 in heterodimerization with the leukemia inhibitory factor receptorMMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancerControlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimersLigand-independent dimerization and activation of the oncogenic Xmrk receptor by two mutations in the extracellular domain.Normal activation of discoidin domain receptor 1 mutants with disulfide cross-links, insertions, or deletions in the extracellular juxtamembrane region: mechanistic implicationsActivation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface.Oncogenic activating mutations in the neu/erbB-2 oncogene are involved in the induction of mammary tumors.Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancerc-erbB2-induced disruption of matrix adhesion and morphogenesis reveals a novel role for protein kinase B as a negative regulator of alpha(2)beta(1) integrin function.Mammary gland neoplasia: insights from transgenic mouse models.HER2/neu: mechanisms of dimerization/oligomerization.Transgenic mouse models of human breast cancer.Oncogenes and tumor suppressor genesE3 ubiquitin ligases in ErbB receptor quantity control.The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisThe ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment.TACE activation by MAPK-mediated regulation of cell surface dimerization and TIMP3 association.Single unpurified breast tumor-initiating cells from multiple mouse models efficiently elicit tumors in immune-competent hosts.Melanoma development and pigment cell transformation in xiphophorus.The role of distinct p185neu extracellular subdomains for dimerization with the epidermal growth factor (EGF) receptor and EGF-mediated signaling.Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation.A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis.The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.Germ-line expression of an oncogenic erbB2 allele confers resistance to erbB2-induced mammary tumorigenesisc-Myc induction of programmed cell death may contribute to carcinogenesis: a perspective inspired by several concepts of chemical carcinogenesis.HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.Mutagenesis reveals a role for epidermal growth factor receptor extracellular subdomain IV in ligand binding.Overview of Genetically Engineered Mouse Models of Breast Cancer Used in Translational Biology and Drug Development.When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase.Molecular modeling of nearly full-length ErbB2 receptor.Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.Scavenging of extracellular H2O2 by catalase inhibits the proliferation of HER-2/Neu-transformed rat-1 fibroblasts through the induction of a stress response.Signaling through Ras is essential for ret oncogene-induced cell differentiation in PC12 cells.The breast cancer susceptibility FGFR2 provides an alternate mode of HER2 activation.Dimerization of the extracellular domain of the receptor for epidermal growth factor containing the membrane-spanning segment in response to treatment with epidermal growth factor.Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer.The Glu632-Leu633 deletion in cysteine rich domain of Ret induces constitutive dimerization and alters the processing of the receptor protein.A novel splice variant of HER2 with increased transformation activity.
P2860
Q24683709-14BB1BB8-6D65-456F-83FA-148B15446D6FQ28202478-5CAA4F93-A1B4-44CD-A27E-14D8BE91694CQ28250940-30B74C29-0A82-415E-8F2B-55C17C933F12Q28679173-2D452A24-EFD9-4D4C-8B7C-8B6C97C779BDQ31473336-173655E6-4418-4CE7-A30A-3DBD16467293Q33676762-B9905E6D-BCA5-423D-843F-F3EBEFE66EB6Q33778555-3B35FC91-9C26-4FA6-9BD7-EC1404571265Q33834290-FE047C6C-2A20-4BCA-8060-7934BA3536FAQ33890758-2C03B769-866E-4EFF-B213-D7A3D057681CQ33903097-3B15D48B-8667-46C0-A98F-060A9868D66EQ33936692-7470DD59-14FB-4F42-ADC5-37CA21E019CFQ34130541-362E5E77-2EF0-465F-8E2C-DBA77CF7D3EDQ34130558-11EB8E76-CD53-47C8-957B-3B64E4C54599Q34149922-334E8224-E735-4792-9407-5CFAED1578F4Q34349106-B2FD00A9-EC7F-43BD-B58E-B886E54F945FQ34493341-1E57552B-EDEC-40E3-924B-3A45117E4A26Q34525673-C4444D19-293A-48F7-9585-875DBF53AAB5Q34626693-D454F614-4D39-49FE-8316-1E2F852EC130Q34650297-B2E99A13-EBDA-43FD-989C-399AF15DE2D3Q34872771-99123886-F962-4529-A94C-D6C057D828D3Q35883970-F9E389CD-2CB9-403E-9225-4E37BED39E89Q36221780-E3EB4FD9-2A22-405C-B368-C62A0143C01AQ37132712-5B4262C5-BF0C-4BEB-9B8C-827CE4C5EDD8Q37233360-66B5A7F6-9168-4957-8835-F0D193048B0BQ37326072-D80FB9A9-88AB-44F5-8905-A6F5C0FB8939Q37415729-D255A4EB-CF02-4758-B0B4-C965C7EE8A6EQ37833424-FE43C329-517A-4CC0-88A9-4A52B7A14678Q38301236-C608AC7D-1DA1-493C-A410-3B4042F59E3AQ38320275-8D3AD2D9-DAFC-4696-AB4E-47185632BC7BQ38578970-6AD65306-560C-413C-9E6E-E0804BC31DF9Q38673589-C6B0A1E3-CC5B-4904-A3F6-2D0CFCE0CEE3Q40316579-C1AB4610-5B5F-4762-8FD4-89A82585929FQ40499571-B1FE6594-58EB-45D1-A7DD-33E09053CE6AQ40832473-249E088C-FC1D-4D31-A815-5CCB79A780F1Q40889507-13D9D191-E493-40EA-BC19-7AF9B375156BQ41499257-B38130AA-A21D-4519-A3D4-B40DCF71D77CQ41705572-0D707B6C-1F30-4195-B080-466C0513CB5CQ42732429-04FD3DD0-3829-4F6F-9912-F868F9C009C8Q42810837-5F2EE4F4-6674-4955-941A-E2AE9189D501Q42824817-9ECAA6AD-AC26-4C40-AC2D-3EE9FF64A3DA
P2860
Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mutations affecting conserved ...... r dimerization and activation.
@en
Mutations affecting conserved ...... r dimerization and activation.
@nl
type
label
Mutations affecting conserved ...... r dimerization and activation.
@en
Mutations affecting conserved ...... r dimerization and activation.
@nl
prefLabel
Mutations affecting conserved ...... r dimerization and activation.
@en
Mutations affecting conserved ...... r dimerization and activation.
@nl
P2860
P356
P1476
Mutations affecting conserved ...... r dimerization and activation.
@en
P2093
P2860
P304
P356
10.1073/PNAS.93.17.8878
P407
P577
1996-08-01T00:00:00Z